Loading stock data…
VERU
$3.05-0.05 (-1.61%)
Market OpenUpdated 1:29 PM EDT
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Veru Inc. in the Healthcare sector is trading at $3.05. Wall Street consensus targets $24.50 (2 analysts), implying a +703.3% move over the next 12 months. The stock is currently near its 52-week low of $2.05, remaining 11.3% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +703.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.22M↓ | -$5.42M↑ | -$7.46M↑ | -$8.03M↑ | -$9.10M |
| Net Income | -$2.74M↑ | -$5.33M↓ | $1.45M↑ | -$7.33M↑ | -$7.90M |
Peer Comparison
JNJUNHPFE
Fundamentals
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 fe...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-40.11%
Volume
Today's trading volume
602,725
Recent News
Veru And 2 Other Intriguing Penny Stocks To Watch
In the last week, the market has stayed flat, but it is up 26% over the past year with earnings forecast to grow by 16% annually. Investing in penny stocks — though somewhat of an outdated term — still presents opportunities for growth, particularly in smaller or newer companies. By focusing on those with strong financial health and potential for future growth, investors can find intriguing prospects that may offer both stability and upside.
Novo Nordisk Tests Wegovy Combinations In Older Adults With Veru Trial
Novo Nordisk (CPSE:NOVO B) has signed a clinical supply agreement with Veru Inc. to provide Wegovy for a Phase 2b obesity trial in older adults. The PLATEAU study will test Wegovy alongside Veru’s enobosarm, a selective androgen receptor modulator, in combination therapy. Novo Nordisk retains no development rights to enobosarm but has secured a right of first negotiation for potential future collaborations with Veru. For investors tracking CPSE:NOVO B, this agreement comes as the share...
This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection?
Veru will evaluate enobosarm alongside Novo Nordisk’s Wegovy in the Phase 2b PLATEAU trial in older adults with obesity.
Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU)
Veru Inc. (NASDAQ:VERU) has entered into a clinical supply agreement with Novo Nordisk A/S (NYSE:NVO) to support its upcoming Phase 2b PLATEAU study, which will investigate a combination treatment for obesity in older adults.
Earnings call transcript: Veru Inc Q2 2026 shows improved financials
Veru Inc. reported a substantial improvement in its Q2 fiscal year 2026 financial performance, marked by a significant reduction in net loss and operating expenses. With a focus on its lead asset, enobosarm, Veru continues to drive innovation in obesity treatment. Veru Inc. demonstrated a marked improvement in its financial health during Q2 FY2026.